Workflow
通用型细胞疗法
icon
Search documents
2025年中国免疫细胞治疗产品行业研究:百亿市场加速扩容,国产创新迈向全球引领
Tou Bao Yan Jiu Yuan· 2025-10-09 14:45
Investment Rating - The report indicates a strong investment outlook for the immune cell therapy products industry in China, projecting significant market growth and innovation opportunities [6][23]. Core Insights - The immune cell therapy market in China is experiencing rapid expansion, with the market size increasing from approximately 1.5 billion yuan in 2019 to nearly 5.5 billion yuan in 2023, and is expected to exceed 10 billion USD by 2030 [6][23]. - The industry is focusing on overcoming clinical challenges in solid tumor treatments, with innovative technologies like TCR-T and CAR-NK gaining traction [6][23]. - The regulatory environment is improving, with policies supporting the commercialization of cell therapies and encouraging the use of real-world data [6][20]. Summary by Sections Industry Overview - The immune cell therapy products are defined as biological agents made from activated or genetically modified immune cells, including CAR-T, TCR-T, and NK cells [15][17]. - The development of immune cell therapy in China has progressed through five stages: theoretical foundation, technological exploration, engineering breakthroughs, industrialization, and innovation [17][20]. Market Size - The global immune cell therapy market is projected to grow from 1.189 billion USD in 2019 to 4.353 billion USD in 2024, with a compound annual growth rate (CAGR) driven by breakthroughs in blood cancer treatments [23][24]. - China's market is expected to grow from 220 million USD in 2019 to 750 million USD in 2024, with a potential to surpass 10.85 billion USD by 2030 [23][24]. Industry Chain Analysis - The industry chain consists of upstream suppliers of raw materials and equipment, midstream R&D and production companies, and downstream medical institutions and patients [31][32]. - The cost structure in the upstream production process is shifting towards capital-intensive models, with raw material costs remaining a critical factor [35][38]. Development Trends - The industry is witnessing a surge in IND applications, with 58 approvals expected in 2024, marking a significant increase from previous years [39][41]. - The focus is shifting from homogeneous competition in target markets to breakthroughs in solid tumors and enhancing accessibility [39][42].